<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="oration" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Medical academic journal</journal-id><journal-title-group><journal-title xml:lang="en">Medical academic journal</journal-title><trans-title-group xml:lang="ru"><trans-title>Медицинский академический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1608-4101</issn><issn publication-format="electronic">2687-1378</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76290</article-id><article-id pub-id-type="doi">10.17816/MAJ76290</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Conference proceedings</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Материалы конференции</subject></subj-group><subj-group subj-group-type="article-type"><subject>Conference Report, Theses of Report</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Protective role of silver nanoparticles in influenza infection</article-title><trans-title-group xml:lang="ru"><trans-title>Защитная роль наночастиц серебра при гриппозной инфекции</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0017-4126</contrib-id><contrib-id contrib-id-type="spin">5075-2110</contrib-id><name-alternatives><name xml:lang="en"><surname>Al Farroukh</surname><given-names>Mohammad</given-names></name><name xml:lang="ru"><surname>Аль Фаррух</surname><given-names>Мохаммад</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Postgraduate student</p></bio><bio xml:lang="ru"><p>аспирант</p></bio><email>mouhammad1farroukh@gmail.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6018-2190</contrib-id><contrib-id contrib-id-type="spin">1544-0664</contrib-id><name-alternatives><name xml:lang="en"><surname>Skomorokhova</surname><given-names>Ekaterina A.</given-names></name><name xml:lang="ru"><surname>Скоморохова</surname><given-names>Екатерина Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Biol.), Researcher</p></bio><bio xml:lang="ru"><p>канд. биол. наук, научный сотрудник</p></bio><email>katjaskom@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1959-7110</contrib-id><contrib-id contrib-id-type="spin">4882-6260</contrib-id><name-alternatives><name xml:lang="en"><surname>Magazenkova</surname><given-names>Daria N.</given-names></name><name xml:lang="ru"><surname>Магазенкова</surname><given-names>Дарья Николаевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>engineer</p></bio><bio xml:lang="ru"><p>инженер, научный сотрудник</p></bio><email>magdash@mail.ru</email><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3892-9873</contrib-id><contrib-id contrib-id-type="spin">7857-7306</contrib-id><name-alternatives><name xml:lang="en"><surname>Kiseleva</surname><given-names>Irina V.</given-names></name><name xml:lang="ru"><surname>Киселева</surname><given-names>Ирина Васильевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Biol.), Professor, Laboratory Head</p></bio><bio xml:lang="ru"><p>д-р биол. наук, профессор, зав. лабораторией</p></bio><email>irina.v.kiseleva@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Institute of Experimental Medicine</institution></aff><aff><institution xml:lang="ru">Институт экспериментальной медицины</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Saint Petersburg State University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский государственный университет</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">ITMO University</institution></aff><aff><institution xml:lang="ru">Национальный исследовательский университет ИТМО</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2021-08-06" publication-format="electronic"><day>06</day><month>08</month><year>2021</year></pub-date><pub-date date-type="pub" iso-8601-date="2021-12-06" publication-format="electronic"><day>06</day><month>12</month><year>2021</year></pub-date><volume>21</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>81</fpage><lpage>84</lpage><history><date date-type="received" iso-8601-date="2021-07-19"><day>19</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-08-06"><day>06</day><month>08</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Al Farroukh M., Skomorokhova E.A., Magazenkova D.N., Kiseleva I.V.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, Аль Фаррух М., Скоморохова Е.А., Магазенкова Д.Н., Киселева И.В.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Al Farroukh M., Skomorokhova E.A., Magazenkova D.N., Kiseleva I.V.</copyright-holder><copyright-holder xml:lang="ru">Аль Фаррух М., Скоморохова Е.А., Магазенкова Д.Н., Киселева И.В.</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/MAJ/article/view/76290">https://journals.eco-vector.com/MAJ/article/view/76290</self-uri><abstract xml:lang="en"><p><bold><italic>BACKGROUND:</italic></bold> The present study assesses copper metabolism of the host organism as a target of antiviral strategy, basing on the “virocell” concept. This concept suggests that the targets for suppressing viral reproduction can be found in the host’s metabolism.</p> <p><bold><italic>AIM:</italic></bold> Evaluation of the effect of copper status indicators on influenza infection in mice.</p> <p><bold><italic>MATERIALS AND METHODS:</italic></bold> Silver nanoparticles (AgNPs) were used as a specific active agent because they reduce the level of holo-ceruloplasmin, the main extracellular cuproenzyme. The mouse model of influenza virus A infection was used with two doses: 1 LD<sub>50</sub> and 10 LD<sub>50</sub>. The following treatment regimens were used: mice were pretreated four days before infection and then every day during infection development until the end of the experiment (day 14).</p> <p><bold><italic>RESULTS:</italic></bold> The mice treated with AgNPs demonstrated significantly lower mortality, the protection index reached 60–70% at the end of the experiment, and mean lifespan was prolonged. In addition, the treatment of the animals with AgNPs resulted in normalization of the weight dynamics. Despite the amelioration of the infection, AgNPs treatment did not influence influenza virus replication.</p> <p><bold><italic>CONCLUSIONS:</italic></bold> This study provides support for the view that silver nanoparticles could be used as protection against influenza.</p></abstract><trans-abstract xml:lang="ru"><p><bold><italic>Обоснование.</italic></bold> В исследовании оценивали метаболизм меди в организме хозяина как цель противовирусной стратегии, основываясь на концепции «вируклеток», предполагающей что мишени для подавления репродукции вируса могут быть найдены в метаболизме хозяина.</p> <p><bold><italic>Цель</italic></bold> — оценить влияние показателей статуса меди на гриппозную инфекцию у мышей.</p> <p><bold><italic>Материалы и методы.</italic></bold> Наночастицы серебра (AgNPs) использовали в качестве специфического активного агента, поскольку они снижают уровень холоцерулоплазмина — основного внеклеточного купроэнзима. В мышиной модели гриппозной инфекции задействовали две дозы вируса гриппа A: 1 ЛД<sub>50</sub> и 10 ЛД<sub>50</sub>. Применяли следующую схему лечения: мышам вводили наночастицы серебра ежедневно, начиная за четыре дня до заражения и до конца эксперимента (14-й день).</p> <p><bold><italic>Результаты исследования.</italic></bold> У мышей, получавших AgNPs, зарегистрирована значительно меньшая смертность, в конце эксперимента индекс защиты достиг 60–70 %, а средняя продолжительность жизни была увеличена. Кроме того, обработка животных AgNPs привела к нормализации динамики их веса. Несмотря на ослабление инфекции, лечение AgNPs не влияло на репликацию вируса гриппа.</p> <p><bold><italic>Заключение.</italic></bold> Исследование подтверждает, что наночастицы серебра могут использоваться для защиты от гриппа.</p></trans-abstract><kwd-group xml:lang="en"><kwd>ceruloplasmin</kwd><kwd>copper status</kwd><kwd>silver nanoparticles</kwd><kwd>influenza</kwd><kwd>influenza virus replication</kwd><kwd>prophylaxis and treatment</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>церулоплазмин</kwd><kwd>статус меди</kwd><kwd>наночастицы серебра</kwd><kwd>грипп</kwd><kwd>репликация вируса гриппа</kwd><kwd>профилактика и лечение</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование выполнено в рамках государственного задания.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Up to 650 000 people die of respiratory diseases linked to seasonal flu each year [Internet]. WHO. 2017. Available from: http://www.who.int/mediacentre/news/releases/2017/seasonal-flu/en/. Accessed: June 2, 2021.</mixed-citation><mixed-citation xml:lang="ru">Up to 650 000 people die of respiratory diseases linked to seasonal flu each year [Электронный ресурс] // WHO. 2017. Режим доступа: http://www.who.int/mediacentre/news/releases/2017/seasonal-flu/en/. Дата обращения: 2.06.2021.</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Forterre P. The virocell concept and environmental microbiology. ISME J. 2013;7(2):233–236. DOI: 10.1038/ismej.2012.110</mixed-citation><mixed-citation xml:lang="ru">Forterre P. The virocell concept and environmental microbiology // ISME J. 2013. Vol. 7, No. 2. P. 233–236. DOI: 10.1038/ismej.2012.110</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Xiang D, Duan W, Shigdar S, et al. Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo. International Journal of Nanomedicine. 2013;8:4103–4113. DOI: 10.2147/ijn.S53622</mixed-citation><mixed-citation xml:lang="ru">Xiang D., Duan W., Shigdar S. et al. Inhibition of A/Human/Hubei/3/2005 (H3N2) influenza virus infection by silver nanoparticles in vitro and in vivo // International Journal of Nanomedicine. 2013. Vol. 8. P. 4103–4113. DOI: 10.2147/ijn.S53622</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Xiang DX, Chen Q, Pang, L, Zheng, CL. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J Virol Methods. 2011;178(1–2):137–142. DOI: 10.1016/j.jviromet.2011.09.003</mixed-citation><mixed-citation xml:lang="ru">Xiang D.X., Chen Q., Pang L., Zheng C.L. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro // J. Virol. Methods. 2011. Vol. 178, No. 1–2. P. 137–142. DOI: 10.1016/j.jviromet.2011.09.003</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Mehrbod P, Motamed N, Tabatabaian M, et al. In vitro antiviral effect of “nanosilver” on influenza virus. DARU Journal of Pharmaceutical Sciences. 2009;17(2):88–93.</mixed-citation><mixed-citation xml:lang="ru">Mehrbod P., Motamed N., Tabatabaian M. et al. In vitro antiviral effect of “nanosilver” on influenza virus // DARU Journal of Pharmaceutical Sciences. 2009. Vol. 17, No. 2. P. 88–93.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
